Quick Answer
REPLIGEN CORP reported R&D Expense of $54.18 million for fiscal year 2025.
REPLIGEN CORP R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $54.18M | +25.4% |
| 2024 | $43.20M | +1.1% |
| 2023 | $42.72M | -2.8% |
| 2022 | $43.94M | +28.2% |
| 2021 | $34.27M | +69.8% |
| 2020 | $20.18M | +3.8% |
| 2019 | $19.45M | +22.9% |
| 2018 | $15.82M | +82.4% |
| 2017 | $8.67M | +17.9% |
| 2016 | $7.36M | +28.1% |
| 2015 | $5.74M | +2.3% |
| 2014 | $5.61M | -23.6% |
| 2013 | $7.34M | -30.0% |
| 2012 | $10.49M | -16.3% |
| 2011 | $12.53M | -11.5% |
| 2010 | $14.16M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $14.18M | +46.0% | +1.6% |
| June 30, 2025 | $13.96M | +32.0% | +8.0% |
| March 31, 2025 | $12.92M | +15.0% | +33.1% |
| September 30, 2024 | $9.71M | -8.2% | -8.2% |
| June 30, 2024 | $10.57M | +9.0% | -5.9% |
| March 31, 2024 | $11.24M | -7.5% | +6.2% |
| September 30, 2023 | $10.58M | +3.4% | +9.0% |
| June 30, 2023 | $9.71M | -7.0% | -20.1% |
- REPLIGEN CORP showed an increase of +25.4% in R&D Expense compared to the prior fiscal year.
- Over the 2010–2025 period, REPLIGEN CORP’s r&d expense has grown by 282.6% (from $14.16 million to $54.18 million).
- The most recent figure is from REPLIGEN CORP’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: